AMRX Quote, Financials, Valuation and Earnings

Innoviva, Inc. has a net margin of 2.31% compared to Amneal Pharmaceuticals, Inc.'s net margin of 80.81%. Amneal Pharmaceuticals, Inc.'s return on equity of -587.3% beat Innoviva, Inc.'s return on equity of 17.06%.

Amneal Pharmaceuticals, Inc. has a consensus price target of $14.40, signalling upside risk potential of 3.23%. On the other hand Innoviva, Inc. has an analysts' consensus of $32.50 which suggests that it could grow by 66.24%. Given that Innoviva, Inc. has higher upside potential than Amneal Pharmaceuticals, Inc., analysts believe Innoviva, Inc. is more attractive than Amneal Pharmaceuticals, Inc..

Amneal Pharmaceuticals, Inc. has a beta of 1.344, which suggesting that the stock is 34.447% more volatile than S&P 500. In comparison Innoviva, Inc. has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.652%.

Amneal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innoviva, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amneal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Innoviva, Inc. pays out -- of its earnings as a dividend.

Amneal Pharmaceuticals, Inc. quarterly revenues are $784.5M, which are larger than Innoviva, Inc. quarterly revenues of $111.3M. Amneal Pharmaceuticals, Inc.'s net income of $18.1M is lower than Innoviva, Inc.'s net income of $89.9M. Notably, Amneal Pharmaceuticals, Inc.'s price-to-earnings ratio is 989.36x while Innoviva, Inc.'s PE ratio is 14.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals, Inc. is 1.52x versus 3.84x for Innoviva, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 2.31% compared to Amneal Pharmaceuticals, Inc.'s net margin of 33.68%. Amneal Pharmaceuticals, Inc.'s return on equity of -587.3% beat Merck & Co., Inc.'s return on equity of 39.63%.

Amneal Pharmaceuticals, Inc. has a consensus price target of $14.40, signalling upside risk potential of 3.23%. On the other hand Merck & Co., Inc. has an analysts' consensus of $117.48 which suggests that it could grow by 9.9%. Given that Merck & Co., Inc. has higher upside potential than Amneal Pharmaceuticals, Inc., analysts believe Merck & Co., Inc. is more attractive than Amneal Pharmaceuticals, Inc..

Amneal Pharmaceuticals, Inc. has a beta of 1.344, which suggesting that the stock is 34.447% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.859%.

Amneal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.07% to investors and pays a quarterly dividend of $0.85 per share. Amneal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Amneal Pharmaceuticals, Inc. quarterly revenues are $784.5M, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Amneal Pharmaceuticals, Inc.'s net income of $18.1M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Amneal Pharmaceuticals, Inc.'s price-to-earnings ratio is 989.36x while Merck & Co., Inc.'s PE ratio is 14.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals, Inc. is 1.52x versus 4.22x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of 2.31% compared to Amneal Pharmaceuticals, Inc.'s net margin of -301.29%. Amneal Pharmaceuticals, Inc.'s return on equity of -587.3% beat Nektar Therapeutics's return on equity of -327.67%.

Amneal Pharmaceuticals, Inc. has a consensus price target of $14.40, signalling upside risk potential of 3.23%. On the other hand Nektar Therapeutics has an analysts' consensus of $114.43 which suggests that it could grow by 218.65%. Given that Nektar Therapeutics has higher upside potential than Amneal Pharmaceuticals, Inc., analysts believe Nektar Therapeutics is more attractive than Amneal Pharmaceuticals, Inc..

Amneal Pharmaceuticals, Inc. has a beta of 1.344, which suggesting that the stock is 34.447% more volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.306, suggesting its more volatile than the S&P 500 by 30.624%.

Amneal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amneal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Amneal Pharmaceuticals, Inc. quarterly revenues are $784.5M, which are larger than Nektar Therapeutics quarterly revenues of $11.8M. Amneal Pharmaceuticals, Inc.'s net income of $18.1M is higher than Nektar Therapeutics's net income of -$35.5M. Notably, Amneal Pharmaceuticals, Inc.'s price-to-earnings ratio is 989.36x while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals, Inc. is 1.52x versus 37.03x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 2.31% compared to Amneal Pharmaceuticals, Inc.'s net margin of 21.32%. Amneal Pharmaceuticals, Inc.'s return on equity of -587.3% beat Pfizer Inc.'s return on equity of 10.84%.

Amneal Pharmaceuticals, Inc. has a consensus price target of $14.40, signalling upside risk potential of 3.23%. On the other hand Pfizer Inc. has an analysts' consensus of $28.78 which suggests that it could grow by 11.3%. Given that Pfizer Inc. has higher upside potential than Amneal Pharmaceuticals, Inc., analysts believe Pfizer Inc. is more attractive than Amneal Pharmaceuticals, Inc..

Amneal Pharmaceuticals, Inc. has a beta of 1.344, which suggesting that the stock is 34.447% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.

Amneal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.65% to investors and pays a quarterly dividend of $0.43 per share. Amneal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Amneal Pharmaceuticals, Inc. quarterly revenues are $784.5M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Amneal Pharmaceuticals, Inc.'s net income of $18.1M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Amneal Pharmaceuticals, Inc.'s price-to-earnings ratio is 989.36x while Pfizer Inc.'s PE ratio is 15.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals, Inc. is 1.52x versus 2.35x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.